| Literature DB >> 26138104 |
Dan H Barouch1, Galit Alter2, Thomas Broge2, Caitlyn Linde2, Margaret E Ackerman3, Eric P Brown3, Erica N Borducchi4, Kaitlin M Smith4, Joseph P Nkolola4, Jinyan Liu4, Jennifer Shields4, Lily Parenteau4, James B Whitney4, Peter Abbink4, David M Ng'ang'a4, Michael S Seaman4, Christy L Lavine4, James R Perry4, Wenjun Li5, Arnaud D Colantonio6, Mark G Lewis7, Bing Chen8, Holger Wenschuh9, Ulf Reimer9, Michael Piatak10, Jeffrey D Lifson10, Scott A Handley11, Herbert W Virgin11, Marguerite Koutsoukos12, Clarisse Lorin12, Gerald Voss12, Mo Weijtens13, Maria G Pau13, Hanneke Schuitemaker13.
Abstract
Preclinical studies of viral vector-based HIV-1 vaccine candidates have previously shown partial protection against neutralization-resistant virus challenges in rhesus monkeys. In this study, we evaluated the protective efficacy of adenovirus serotype 26 (Ad26) vector priming followed by purified envelope (Env) glycoprotein boosting. Rhesus monkeys primed with Ad26 vectors expressing SIVsmE543 Env, Gag, and Pol and boosted with AS01B-adjuvanted SIVmac32H Env gp140 demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIVmac251 challenges that infected all controls. Protective efficacy correlated with the functionality of Env-specific antibody responses. Comparable protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarectal SHIV-SF162P3 challenges. These data demonstrate robust protection by Ad/Env vaccines against acquisition of neutralization-resistant virus challenges in rhesus monkeys.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26138104 PMCID： PMC4653134 DOI： 10.1126/science.aab3886
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728